Cure8 research brief
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and delay reliable biomarker development for UC treatment.
Researchers working on gene-expression or biomarker prediction for IBD, clinical investigators planning predictive-model studies, and clinicians following biomarker development for infliximab response.
The author linked pretreatment gene-expression records to individual patients across public datasets and tested how reusing the same patient’s data in both training and test sets affects model performance.
Excluding all records from the same patient reduced measured predictive performance modestly, but uncertainty intervals included no clear difference and results were sensitive to single patients.
The paper also tested how probe selection and scaling change a published 1,007-gene score in one dataset: different preprocessing reduced the difference between responders and nonresponders, though nonresponders still had higher average scores under the tested settings.
The study’s main point is methodological — it urges researchers to check for patient overlap and to report preprocessing choices when evaluating gene-expression predictors of drug response.
Findings are from a preprint and focus on methodological checks (patient overlap, probe selection, scaling) rather than demonstrating a clinically validated test. Results were sensitive to individual patients and to preprocessing choices.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
